Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 14,900 shares, a growth of 144.3% from the November 15th total of 6,100 shares. Based on an average daily trading volume, of 16,600 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.7% of the shares of the stock are sold short.
Institutional Trading of Daxor
An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC raised its holdings in shares of Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. Institutional investors own 1.34% of the company’s stock.
Analyst Ratings Changes
Separately, Ascendiant Capital Markets upped their target price on shares of Daxor from $24.50 to $24.75 and gave the company a “buy” rating in a research report on Monday, September 9th.
Daxor Stock Down 2.9 %
Shares of NASDAQ DXR traded down $0.24 during mid-day trading on Friday, hitting $8.16. 9,171 shares of the company’s stock traded hands, compared to its average volume of 7,580. The company’s 50-day moving average is $9.05 and its two-hundred day moving average is $8.98. Daxor has a 1 year low of $7.16 and a 1 year high of $10.04.
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Articles
- Five stocks we like better than Daxor
- Breakout Stocks: What They Are and How to Identify Them
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Trading Stocks: RSI and Why it’s Useful
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Short Selling: How to Short a Stock
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.